Philip A. Efron
University of Florida
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Philip A. Efron.
Journal of Trauma-injury Infection and Critical Care | 2012
Lori F. Gentile; Alex G. Cuenca; Philip A. Efron; Darwin N. Ang; Azra Bihorac; Bruce A. McKinley; Lyle L. Moldawer; Frederick A. Moore
ABSTRACT Surgical intensive care unit (ICU) stay of longer than 10 days is often described by the experienced intensivist as a “complicated clinical course” and is frequently attributed to persistent immune dysfunction. “Systemic inflammatory response syndrome” (SIRS) followed by “compensatory anti-inflammatory response syndrome” (CARS) is a conceptual framework to explain the immunologic trajectory that ICU patients with severe sepsis, trauma, or emergency surgery for abdominal infection often traverse, but the causes, mechanisms, and reasons for persistent immune dysfunction remain unexplained. Often involving multiple-organ failure (MOF) and death, improvements in surgical intensive care have altered its incidence, phenotype, and frequency and have increased the number of patients who survive initial sepsis or surgical events and progress to a persistent inflammation, immunosuppression, and catabolism syndrome (PICS). Often observed, but rarely reversible, these patients may survive to transfer to a long-term care facility only to return to the ICU, but rarely to self-sufficiency. We propose that PICS is the dominant pathophysiology and phenotype that has replaced late MOF and prolongs surgical ICU stay, usually with poor outcome. This review details the evolving epidemiology of MOF, the clinical presentation of PICS, and our understanding of how persistent inflammation and immunosuppression define the pathobiology of prolonged intensive care. Therapy for PICS will involve innovative interventions for immune system rebalance and nutritional support to regain physical function and well-being.
Molecular Medicine | 2011
Alex G. Cuenca; Matthew J. Delano; Kindra M. Kelly-Scumpia; Claudia Moreno; Philip O. Scumpia; Drake LaFace; Paul G. Heyworth; Philip A. Efron; Lyle L. Moldawer
Myeloid-derived suppressor cells (MDSCs) are a heterogenous population of immature myeloid cells whose numbers dramatically increase in chronic and acute inflammatory diseases, including cancer, autoimmune disease, trauma, burns and sepsis. Studied originally in cancer, these cells are potently immunosuppressive, particularly in their ability to suppress antigen-specific CD8+ and CD4+ T-cell activation through multiple mechanisms, including depletion of extracellular arginine, nitrosylation of regulatory proteins, and secretion of interleukin 10, prostaglandins and other immunosuppressive mediators. However, additional properties of these cells, including increased reactive oxygen species and inflammatory cytokine production, as well as their universal expansion in nearly all inflammatory conditions, suggest that MDSCs may be more of a normal component of the inflammatory response (“emergency myelopoiesis”) than simply a pathological response to a growing tumor. Recent evocative data even suggest that the expansion of MDSCs in acute inflammatory processes, such as burns and sepsis, plays a beneficial role in the host by increasing immune surveillance and innate immune responses. Although clinical efforts are currently underway to suppress MDSC numbers and function in cancer to improve antineoplastic responses, such approaches may not be desirable or beneficial in other clinical conditions in which immune surveillance and antimicrobial activities are required.
Journal of Immunology | 2004
Philip A. Efron; Antonio Martins; Douglas J. Minnich; Kevin W. Tinsley; Ricardo Ungaro; Frances R. Bahjat; Richard S. Hotchkiss; Michael Clare-Salzler; Lyle L. Moldawer
Dendritic cells (DCs) play a key role in critical illness and are depleted in spleens from septic patients and mice. To date, few studies have characterized the systemic effect of sepsis on DC populations in lymphoid tissues. We analyzed the phenotype of DCs and Th cells present in the local (mesenteric) and distant (inguinal and popliteal) lymph nodes of mice with induced polymicrobial sepsis (cecal ligation and puncture). Flow cytometry and immunohistochemical staining demonstrated that there was a significant local (mesenteric nodes) and partial systemic (inguinal, but not popliteal nodes) loss of DCs from lymph nodes in septic mice, and that this process was associated with increased apoptosis. This sepsis-induced loss of DCs occurred after CD3+CD4+ T cell activation and loss in the lymph nodes, and the loss of DCs was not preceded by any sustained increase in their maturation status. In addition, there was no preferential loss of either mature/activated (MHCIIhigh/CD86high) or immature (MHCIIlow/CD86low) DCs during sepsis. However, there was a preferential loss of CD8+ DCs in the local and distant lymph nodes. The loss of DCs in lymphoid tissue, particularly CD8+ lymphoid-derived DCs, may contribute to the alterations in acquired immune status that frequently accompany sepsis.
Journal of Immunology | 2006
Philip O. Scumpia; Matthew J. Delano; Kindra M. Kelly; Kerri O'Malley; Philip A. Efron; Priscilla F. McAuliffe; Todd M. Brusko; Ricardo Ungaro; Tolga Barker; James L. Wynn; Mark A. Atkinson; Westley H. Reeves; Michael J. Clare Salzler; Lyle L. Moldawer
Regulatory T cells (Tregs), including natural CD4+CD25+ Tregs and inducible IL-10 producing T regulatory type 1 (TR1) cells, maintain tolerance and inhibit autoimmunity. Recently, increased percentages of Tregs have been observed in the blood of septic patients, and ex vivo-activated Tregs were shown to prevent polymicrobial sepsis mortality. Whether endogenous Tregs contribute to sepsis outcome remains unclear. Polymicrobial sepsis, induced by cecal ligation and puncture, caused an increased number of splenic Tregs compared with sham-treated mice. Splenic CD4+CD25+ T cells from septic mice expressed higher levels of Foxp3 mRNA and were more efficient suppressors of CD4+CD25− T effector cell proliferation. Isolated CD4+ T cells from septic mice displayed increased intracellular IL-10 staining following stimulation, indicating that TR1 cells may also be elevated in sepsis. Surprisingly, Ab depletion of total CD4+ or CD4+CD25+ populations did not affect mortality. Furthermore, no difference in survival outcome was found between CD25 or IL-10 null mice and wild-type littermates, indicating that Treg or TR1-generated IL-10 are not required for survival. These results demonstrate that, although sepsis causes a relative increase in Treg number and increases their suppressive function, their presence does not contribute significantly to overall survival in this model.
Journal of Immunology | 2011
Matthew J. Delano; Terri C. Thayer; Sonia Gabrilovich; Kindra M. Kelly-Scumpia; Robert D. Winfield; Philip O. Scumpia; Alex G. Cuenca; Elizabeth A. Warner; Shannon M. Wallet; Mark A. Wallet; Kerri O'Malley; Reuben Ramphal; Michael Clare-Salzer; Philip A. Efron; Clayton E. Mathews; Lyle L. Moldawer
Sepsis, the systemic inflammatory response to microbial infection, induces changes in both innate and adaptive immunity that presumably lead to increased susceptibility to secondary infections, multiorgan failure, and death. Using a model of murine polymicrobial sepsis whose severity approximates human sepsis, we examined outcomes and defined requirements for survival after secondary Pseudomonas aeruginosa pneumonia or disseminated Listeria monocytogenes infection. We demonstrate that early after sepsis neutrophil numbers and function are decreased, whereas monocyte recruitment through the CCR2/MCP-1 pathway and function are enhanced. Consequently, lethality to Pseudomonas pneumonia is increased early but not late after induction of sepsis. In contrast, lethality to listeriosis, whose eradication is dependent upon monocyte/macrophage phagocytosis, is actually decreased both early and late after sepsis. Adaptive immunity plays little role in these secondary infectious responses. This study demonstrates that sepsis promotes selective early, impaired innate immune responses, primarily in neutrophils, that lead to a pathogen-specific, increased susceptibility to secondary infections.
Journal of Immunology | 2005
Philip O. Scumpia; Priscilla F. McAuliffe; Kerri O'Malley; Ricardo Ungaro; Takefumi Uchida; Tadashi Matsumoto; Daniel G. Remick; Michael Clare-Salzler; Lyle L. Moldawer; Philip A. Efron
CD11c+ dendritic cells (DCs) are APCs that link innate and adaptive immunity. Although DCs are lost from spleen and lymph nodes in sepsis, their role in outcome remains unclear. Transgenic mice (B6.FVB-Tg.Itgax-DTR/EGFP.57Lan/J) expressing the diphtheria toxin (DT) receptor on the CD11c promoter (DCKO mice) received 4 ng/kg DT, which resulted in depletion of 88–95% of mature myeloid and lymphoid DCs, with less depletion (75%) of plasmacytoid DCs. Pretreatment of DCKO mice with DT resulted in reduced survival in sepsis compared with saline-pretreated DCKO mice (0 vs 54%; p < 0.05) or DT-treated wild-type littermates (0 vs 54%; p < 0.05). This increased mortality was not associated with either increased bacteremia or plasma cytokine concentrations. Intravenous injection of 107 wild-type DCs improved survival in DCKO mice (42 vs 0%; p = 0.05). These data confirm that DCs are essential in the septic response and suggest that strategies to maintain DC numbers or function may improve outcome.
Journal of Experimental Medicine | 2011
Kindra M. Kelly-Scumpia; Philip O. Scumpia; Jason S. Weinstein; Matthew J. Delano; Alex G. Cuenca; Dina C. Nacionales; James L. Wynn; Pui Y. Lee; Yutaro Kumagai; Philip A. Efron; Shizuo Akira; Clive Wasserfall; Mark A. Atkinson; Lyle L. Moldawer
Type I interferon–responsive B cells provide early protection against bacterial sepsis.
Journal of Burn Care & Rehabilitation | 2004
Philip A. Efron; Lyle L. Moldawer
Wound healing is an integrated and complex process involving a large number of regulatory molecules, including proinflammatory cytokines and growth factors, and an orchestrated tissue response. Dysregulation in cytokine or growth factor expression dramatically alters the normal wound healing process, and blocking the inappropriate production of specific proinflammatory cytokines or supplementing the milieu with increased quantities of growth factors has demonstrated the central role played by these mediators. Both protein-based and DNA-based (gene transfer) therapies are currently under clinical development as tools to improve the healing process. Although there has been some success with these approaches in both experimental models and in patients, only through a better understanding of the complexity and diversity of the wound healing process, as well as an improved comprehension of the time-dependent and concentration-dependent responses to individual proinflammatory cytokines or growth factors, will further development in the therapeutic treatment of healing wounds be attained.
Annals of Surgery | 2015
Charles Hobson; Tezcan Ozrazgat-Baslanti; Adrienne Kuxhausen; Paul Thottakkara; Philip A. Efron; Frederick A. Moore; Lyle L. Moldawer; Mark S. Segal; Azra Bihorac
OBJECTIVE To determine the incremental hospital cost and mortality associated with the development of postoperative acute kidney injury (AKI) and with other associated postoperative complications. BACKGROUND Each year 1.5 million patients develop a major complication after surgery. Postoperative AKI is one of the most common postoperative complications and is associated with an increase in hospital mortality and decreased survival for up to 15 years after surgery. METHODS In a single-center cohort of 50,314 adult surgical patients undergoing major inpatient surgery, we applied risk-adjusted regression models for cost and mortality using postoperative AKI and other complications as the main independent predictors. We defined AKI using consensus Risk, Injury, Failure, Loss and End-Stage Renal Disease criteria. RESULTS The prevalence of AKI was 39% among 50,314 patients with available serum creatinine. Patients with AKI were more likely to have postoperative complications and had longer lengths of stay in the intensive care unit and the hospital. The risk-adjusted average cost of care for patients undergoing surgery was
Shock | 2003
Philip A. Efron; Lyle L. Moldawer
42,600 for patients with any AKI compared with